OCUGEN, INC. (OCGN) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 20.00K USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 1.73M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 124.21M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $20.00K | $1.73M | (m) | (m) | $124.21M | (m) |
| 2026-03-31 | (m) | (m) | $5.00M | $24.19M | (m) | (m) | $56.91M | (m) |
| 2025-12-31 | (m) | (m) | $1.25M | $27.54M | (m) | (m) | $43.52M | (m) |
| 2025-09-30 | (m) | (m) | $0.00 | $28.40M | (m) | (m) | $57.60M | (m) |
| 2025-06-30 | (m) | (m) | $0.00 | $28.02M | (m) | (m) | $53.59M | (m) |
| 2025-03-31 | (m) | (m) | $0.00 | $27.67M | (m) | (m) | $64.46M | (m) |
| 2024-12-31 | (m) | (m) | $1.33M | $27.34M | (m) | (m) | $82.44M | (m) |
| 2024-09-30 | (m) | (m) | $1.32M | $1.57M | (m) | (m) | $61.94M | (m) |
| 2024-06-30 | (m) | (m) | $1.31M | $1.55M | (m) | (m) | $40.54M | (m) |
| 2024-03-31 | (m) | (m) | $1.30M | $1.53M | (m) | (m) | $51.79M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $2.80M | (m) | $39.46M | $64.55M | (m) |
| 2023-09-30 | (m) | (m) | $1.28M | $1.50M | (m) | $53.48M | $74.69M | (m) |
| 2023-06-30 | (m) | (m) | $1.27M | $1.47M | (m) | $70.58M | $88.98M | (m) |
| 2023-03-31 | (m) | (m) | $1.26M | $1.06M | (m) | $76.72M | $96.30M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $2.29M | (m) | $90.93M | $108.63M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $2.27M | (m) | (m) | $116.24M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $1.75M | (m) | (m) | $130.09M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $1.73M | (m) | (m) | $141.73M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $1.71M | (m) | (m) | $105.76M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $1.69M | (m) | (m) | $116.31M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $1.67M | (m) | (m) | $124.25M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $1.70M | (m) | (m) | $53.85M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $1.82M | (m) | (m) | $27.38M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $1.94M | (m) | (m) | $20.54M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $2.02M | (m) | (m) | $23.76M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $1.58M | (m) | (m) | $12.31M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $1.07M | (m) | (m) | $16.81M | (m) |
| 2019-09-30 | (m) | (m) | (m) | $1.06M | (m) | (m) | $23.62M | (m) |
| 2019-06-30 | (m) | (m) | (m) | $1.05M | (m) | (m) | $4.12M | (m) |
| 2018-12-31 | (m) | (m) | (m) | $1.02M | (m) | (m) | $2.45M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |